Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Aliment Pharmacol Ther ; 28(3): 344-52, 2008 Aug 01.
Article in English | MEDLINE | ID: mdl-19086332

ABSTRACT

BACKGROUND: Symptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT3R antagonist alosetron is correlated with reduced amygdala activity. AIM: To determine whether neural activity during rectal discomfort or psychological distress predicts symptom improvement following treatment with alosetron. METHODS: Basal psychological distress and neural activity (15O PET) during uncomfortable rectal stimulation were measured in 17 nonconstipated IBS patients who then received 3 weeks of alosetron treatment. RESULTS: Greater symptom improvement was predicted by less activity in bilateral orbitofrontal cortex (OFC) and medial temporal gyrus during pre-treatment scans. Lower levels of interpersonal sensitivity predicted greater symptom improvement and were positively related to activity in left OFC. Connectivity analysis revealed a positive relationship between activity in the left OFC and right amygdala. CONCLUSIONS: Irritable bowel disease symptom improvement with 5-HT3R antagonist alosetron is related to pre-treatment reactivity of the left OFC, which may be partially captured by subjective measures of interpersonal sensitivity. The left OFC may fail to modulate amygdala response to visceral stimulation, thereby diminishing effectiveness of treatment. Psychological factors and their neurobiological correlates are plausible predictors of IBS treatment outcome.


Subject(s)
Brain/drug effects , Carbolines/therapeutic use , Irritable Bowel Syndrome/drug therapy , Rectum/drug effects , Serotonin Receptor Agonists/therapeutic use , Stress, Psychological/drug therapy , Adult , Brain/diagnostic imaging , Brain/physiopathology , Double-Blind Method , Female , Humans , Irritable Bowel Syndrome/diagnostic imaging , Irritable Bowel Syndrome/physiopathology , Male , Pilot Projects , Positron-Emission Tomography , Rectum/diagnostic imaging , Rectum/physiopathology , Retrospective Studies , Stress, Psychological/diagnostic imaging , Stress, Psychological/physiopathology , Treatment Outcome
2.
Am Psychol ; 56(9): 717-34, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11558357

ABSTRACT

Social cognitive neuroscience is an emerging interdisciplinary field of research that seeks to understand phenomena in terms of interactions between 3 levels of analysis: the social level, which is concerned with the motivational and social factors that influence behavior and experience; the cognitive level, which is concerned with the information-processing mechanisms that give rise to social-level phenomena; and the neural level, which is concerned with the brain mechanisms that instantiate cognitive-level processes. The social cognitive neuroscience approach entails conducting studies and constructing theories that make reference to all 3 levels and contrasts with traditional social psychological and cognitive neuroscientific research that primarily makes reference to 2 levels. The authors present an introduction to and analysis of the field by reviewing current research and providing guidelines and suggested directions for future work.


Subject(s)
Neurosciences/trends , Psychology, Social/trends , Social Behavior , Forecasting , Humans , Research , Specialization/trends , United States
3.
Psychol Sci ; 12(2): 135-40, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11340922

ABSTRACT

In two studies, we investigated the roles of explicit memory and attentional resources in the process of behavior-induced attitude change. Although most theories of attitude change (cognitive dissonance and self-perception theories) assume an important role for both mechanisms, we propose that behavior-induced attitude change can be a relatively automatic process that does not require explicit memory for, or consciously controlled processing of, the discrepancy between attitude and behavior. Using a free-choice paradigm, we found that both amnesics and normal participants under cognitive load showed as much attitude change as did control participants.


Subject(s)
Amnesia, Anterograde/psychology , Attention , Attitude , Cognitive Dissonance , Memory, Short-Term , Adolescent , Adult , Aged , Aging/psychology , Case-Control Studies , Female , Humans , Male , Middle Aged , Models, Psychological
4.
J Pers Soc Psychol ; 80(2): 294-310, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11220447

ABSTRACT

Despite personality theories suggesting that extraversion correlates with social skill, most studies have not found a positive correlation between extraversion and nonverbal decoding. The authors propose that introverts are less able to multitask and thus are poorer at nonverbal decoding, but only when it is a secondary task. Prior research has uniformly extracted the nonverbal decoding from its multitasking context and, consequently, never tested this hypothesis. In Studies 1-3, introverts exhibited a nonverbal decoding deficit, relative to extraverts, but only when decoding was a secondary rather than a primary task within a multitasking context. In Study 4, extraversion was found to correlate with central executive efficiency (r = .42) but not with storage capacity (r = .04). These results are discussed in terms of arousal theories of extraversion and the role of catecholamines (dopamine and norepinephrine) in prefrontal function.


Subject(s)
Arousal , Interpersonal Relations , Introversion, Psychological , Nonverbal Communication , Social Perception , Attention , Catecholamines/metabolism , Female , Humans , Male , Memory, Short-Term , Models, Psychological , Neurochemistry , Regression Analysis , Tape Recording , Verbal Behavior
5.
Am J Surg ; 180(2): 117-20, 2000 Aug.
Article in English | MEDLINE | ID: mdl-11044525

ABSTRACT

BACKGROUND: Pancreatic anastomotic failure has historically been regarded as one of the most feared complications after pancreaticoduodenectomy. METHODS: We reviewed our recent experience (59 cases), March 1994 to December 1998, with pancreaticoduodenectomy and compared preoperative and intraoperative characteristics as well as outcomes in those patients who experienced (n = 10) versus those who did not experience a postoperative pancreatic leak (n = 49). Information was retrospectively collected from hospital records, office records, and interviews with patients. RESULTS: The clinical leak rate in this series was 8.5%. There were no significant differences in preoperative or intraoperative characteristics comparing those with versus those without a postoperative pancreatic leak. Only 1 of 10 patients with a postoperative pancreatic leak required reoperation to manage the leak. Those with a pancreatic leak had more other postoperative complications (median 2 versus 0 complications per patient, P = 0.01) and longer hospital duration compared with those without a leak (median 13 versus 23 days, P<0.01). Overall mortality in the series was 3.4%; no mortalities occurred as a result of a pancreatic leak. CONCLUSIONS: In the 1990s pancreatic anastomotic leak remains a potentially lethal problem after pancreaticoduodenectomy. Pancreatic leakage after pancreaticoduodenectomy is associated with other postoperative complications and a longer hospital stay.


Subject(s)
Pancreaticoduodenectomy , Aged , Anastomosis, Surgical , Humans , Length of Stay , Middle Aged , Pancreatic Juice , Postoperative Complications , Reoperation , Retrospective Studies , Treatment Failure
6.
Psychol Bull ; 126(1): 109-37, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10668352

ABSTRACT

This review proposes that implicit learning processes are the cognitive substrate of social intuition. This hypothesis is supported by (a) the conceptual correspondence between implicit learning and social intuition (nonverbal communication) and (b) a review of relevant neuropsychological (Huntington's and Parkinson's disease), neuroimaging, neurophysiological, and neuroanatomical data. It is concluded that the caudate and putamen, in the basal ganglia, are central components of both intuition and implicit learning, supporting the proposed relationship. Parallel, but distinct, processes of judgment and action are demonstrated at each of the social, cognitive, and neural levels of analysis. Additionally, explicit attempts to learn a sequence can interfere with implicit learning. The possible relevance of the computations of the basal ganglia to emotional appraisal, automatic evaluation, script processing, and decision making are discussed.


Subject(s)
Basal Ganglia/anatomy & histology , Basal Ganglia/physiology , Cognition/physiology , Intuition/physiology , Learning/physiology , Female , Humans , Male , Models, Neurological , Nonverbal Communication , Sex Characteristics , Social Perception
7.
Cancer Gene Ther ; 6(6): 491-8, 1999.
Article in English | MEDLINE | ID: mdl-10608345

ABSTRACT

We hypothesize that adenovirus (Ad) vector-mediated delivery of the human interleukin-2 (IL-2) cDNA (AdIL2) or the murine IL-12 cDNA heterodimer (AdIL12) would produce high concentrations of cytokines in the local hepatic milieu to induce host responses sufficient to inhibit the growth of experimental colon carcinoma-derived hepatic metastases. Ad vectors administered intravenously, which is a route known to deliver >90% of the vector to the hepatic parenchyma, achieved significant levels of each cytokine locally, with minimal levels in the sera. To examine the therapeutic effect, the AdIL2 and AdIL12 vectors were evaluated in a hepatic metastasis model that was established by injecting 3 x 10(4) cells from the poorly immunogenic syngeneic C26 colon carcinoma cell line into the right lobe of the livers of BALB/c mice. Animals received AdIL2, AdIL12, or control virus (10(8) plaque-forming units each) intravenously for 2 days after tumor implantation, and tumor growth was compared with naive controls. The AdNull control tumors measured 116 +/- 25 mm2 at 2 weeks. The control virus showed no significant antitumor effect. In marked contrast, both AdIL2 and AdIL12 vectors that were delivered regionally had significant antitumor effects, with AdIL2-treated animals having an average tumor size of 16 +/- 8 mm2; AdIL12-treated tumors measured 6 +/- 6 mm2 (P < .01, both compared with control). Both the AdIL2 and AdIL12 vectors provided a significant survival advantage by log-rank analysis (P < .01), but only AdIL12 translated into an increase in mean survival from 27 (naive control) to 37 days. To evaluate whether these antitumor effects were T-cell-mediated, splenocytes from AdIL2-treated, AdIL12-treated, and naive control groups were stimulated in vitro with gamma-irradiated C26 tumor cells for 5 days and tested for C26 tumor cell cytolysis by an in vitro cytotoxicity assay. Splenocytes from both AdIL2- and AdIL12-treated animals showed a dose-dependent, T-cell-mediated, specific cytolysis of CT26 cells. AdIL12 and to a lesser extent AdIL2 induced natural killer cell activity, as determined by a dose-dependent increase in lysis of the natural killer-specific target cell YAC-1. Overall, these data suggest that regional Ad-mediated delivery of IL-2 and IL-12 cDNAs may be useful for local tumor control and may warrant further investigation as a potentially useful adjuvant for the treatment of hepatic micrometastasis.


Subject(s)
Adenoviridae/genetics , Genetic Therapy , Interleukin-12/genetics , Interleukin-2/genetics , Liver Neoplasms, Experimental/secondary , Liver Neoplasms, Experimental/therapy , Animals , DNA, Complementary , Genetic Vectors , Humans , Interleukin-12/biosynthesis , Interleukin-2/biosynthesis , Killer Cells, Natural/immunology , Liver Neoplasms, Experimental/immunology , Mice , Mice, Inbred BALB C , Survival Analysis , T-Lymphocytes, Cytotoxic/immunology
8.
J Virol ; 73(8): 6729-42, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10400771

ABSTRACT

Administration of adenovirus (Ad) vectors to immunologically naive experimental animals almost invariably results in the induction of systemic anti-Ad neutralizing antibodies. To determine if the human systemic humoral host responses to Ad vectors follow a similar pattern, we evaluated the systemic (serum) anti-Ad serotype 5 (Ad5) neutralizing antibodies in humans after administration of first generation (E1(-) E3(-)) Ad5-based gene transfer vectors to different hosts. AdGVCFTR.10 (carrying the normal human cystic fibrosis [CF] transmembrane regulator cDNA) was sprayed (8 x 10(7) to 2 x 10(10) particle units [PU]) repetitively (every 3 months or every 2 weeks) to the airway epithelium of 15 individuals with CF. AdGVCD.10 (carrying the Escherichia coli cytosine deaminase gene) was administered (8 x 10(8) to 8 x 10(9) PU; once a week, twice) directly to liver metastasis of five individuals with colon cancer and by the intradermal route (8 x 10(7) to 8 x 10(9) PU, single administration) to six healthy individuals. AdGVVEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 10(8) to 4 x 10(9.5) PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease. Ad vector administration to the airways of individuals with CF evoked no or minimal serum neutralizing antibodies, even with repetitive administration. In contrast, intratumor administration of an Ad vector to individuals with metastatic colon cancer resulted in a robust antibody response, with anti-Ad neutralizing antibody titers of 10(2) to >10(4). Healthy individuals responded to single intradermal Ad vector variably, from induction of no neutralizing anti-Ad antibodies to titers of 5 x 10(3). Likewise, individuals with ischemic heart disease had a variable response to single intramyocardial vector administration, ranging from minimal neutralizing antibody levels to titers of 10(4). Evaluation of the data from all trials showed no correlation between the peak serum neutralizing anti-Ad response and the dose of Ad vector administered (P > 0.1, all comparisons). In contrast, there was a striking correlation between the peak anti-Ad5 neutralizing antibody levels evoked by vector administration and the level of preexisting anti-Ad5 antibodies (P = 0.0001). Thus, unlike the case for experimental animals, administration of Ad vectors to humans does not invariably evoke a systemic anti-Ad neutralizing antibody response. In humans, the extent of the response is dictated by preexisting antibody titers and modified by route of administration but is not dose dependent. Since the extent of anti-Ad neutralizing antibodies will likely modify the efficacy of administration of Ad vectors, these observations are of fundamental importance in designing human gene therapy trials and in interpreting the efficacy of Ad vector-mediated gene transfer.


Subject(s)
Adenoviruses, Human/immunology , Antibodies, Viral/immunology , Gene Transfer Techniques , Genetic Vectors/immunology , Adolescent , Adult , Aged , Antibody Formation , Colonic Neoplasms/therapy , Coronary Disease/therapy , Cystic Fibrosis/therapy , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cytosine Deaminase , Endothelial Growth Factors/genetics , Female , Humans , Injections, Intradermal , Liver Neoplasms/secondary , Lymphokines/genetics , Male , Middle Aged , Neutralization Tests , Nucleoside Deaminases/genetics , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
9.
Nutrition ; 14(7-8): 611-7, 1998.
Article in English | MEDLINE | ID: mdl-9684265

ABSTRACT

Clearly, arginine has great potential as an immunomodulator and may prove useful in catabolic conditions such as severe sepsis and postoperative stress. there is a body of evidence suggesting that supplemental arginine upregulates immune function and reduces the incidence of postoperative infection. More modest improvements in nitrogen balance have been observed. Tumor response to arginine appears to depend on the immunogenicity of the particular tumor and on the requirement of arginine by the tumor as a growth substrate. Of note, ornithine shares the thymotrophic, immunostimulatory and secretagogue effects of arginine. It is, therefore, likely that these compounds share the same cellular mechanism of action or that arginine acts via increasing the concentration of available ornithine. The role of arginine in the injured patient and in the tumor-bearing host demands additional study based on the promising experimental evidence regarding the supplemental use of arginine.


Subject(s)
Arginine/physiology , Immunity , Nutritional Physiological Phenomena , Animals , Arginine/administration & dosage , Arginine/chemistry , Arginine/metabolism , Dietary Supplements , Humans , Postoperative Complications , Sepsis , Wounds and Injuries
10.
CA Cancer J Clin ; 48(2): 69-80, 1998.
Article in English | MEDLINE | ID: mdl-9522822

ABSTRACT

Malnutrition, a common problem in cancer patients, adversely affects survival and quality of life. It results from several factors that alter nutritional intake and cause massive metabolic disturbances. Anticancer therapies may compound the malnutrition. Optimal nutrition improves therapeutic modalities and the clinical course and outcome. Oral nutrition should be used whenever possible; in patients unable to ingest adequate amounts orally, enteral and parenteral feedings are safe and effective.


Subject(s)
Neoplasms/therapy , Nutritional Support , Energy Metabolism , Enteral Nutrition , Humans , Neoplasms/metabolism , Nutrition Assessment , Nutrition Disorders/metabolism , Nutrition Disorders/therapy , Parenteral Nutrition, Total , Quality of Life , Safety , Survival Rate , Treatment Outcome
11.
J Surg Res ; 69(1): 226-31, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9202675

ABSTRACT

Gene therapy may allow targeted delivery of tumoricidal drugs to treat pancreatic cancer. Cytosine deaminase (CD) is a bacterial enzyme that converts the nontoxic agent 5-fluorocytosine (5FC) to the active chemotherapeutic agent 5-fluorouracil (5FU). Neoplastic cells induced to express the CD gene treated with 5FC may generate locally high concentrations of 5FU while minimising systemic toxicity. Replication deficient adenovirus vector carrying the CD gene (AdCMV.CD) was tested for therapeutic efficacy against the murine pancreatic carcinoma cell line Pan02. Pan02 cells were infected in vitro with AdCMV.CD or null vector (Ad.-Null) and were examined for expression of CD messenger RNA (mRNA) (Northern blot) and CD enzymatic function (spectrophotometry). mRNA transcripts of the CD gene increased in a dose-dependent manner after infection with AdCMV.CD. Conversion of 5FC to 5FU at a multiplicity of infection (MOI) of 20 was measured to be 51% after a 48-hr incubation. Growth inhibition was measured by MTT assay and thymidine uptake. Pan02 growth in vitro treated with AdCMV.CD and 5FC was inhibited by 80% as compared to cells treated with Ad.Null and 5FC. An in vivo model of pancreatic cancer was established by injecting 2.5 x 10(5) PAN02 cells subcutaneously into the flanks of C57BL/ 6 mice. Seven days later AdCMV.CD was injected into each tumor and 5FC was administered for 10 days. Treatment of mice with AdCMV.CD and 5FC inhibited tumor growth compared to mice who received AdCMV.CD only or 5FC only. These data demonstrate the therapeutic efficacy of an enzyme prodrug strategy in experimental pancreatic cancer.


Subject(s)
Adenoviridae/genetics , Gene Transfer Techniques , Genetic Therapy , Genetic Vectors , Pancreatic Neoplasms/therapy , Animals , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/therapy , Cell Division , Cytosine Deaminase , Escherichia coli/enzymology , Escherichia coli/genetics , Flucytosine/therapeutic use , Mice , Mice, Inbred C57BL , Nucleoside Deaminases/genetics , Nucleoside Deaminases/metabolism , Pancreatic Neoplasms/pathology , Prodrugs/therapeutic use , RNA, Messenger/metabolism
12.
Surgery ; 120(2): 354-9, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8751604

ABSTRACT

BACKGROUND: The epidermal growth factor (EGF) signal transduction pathway, frequently activated in pancreatic cancer, is an important regulator of cellular growth and transformation. This study examined whether activation of the cyclic adenosine monophosphate protein kinase A pathway may inhibit the EGF signal transduction pathway in pancreatic cancer cell lines. METHODS: Human pancreatic cancer lines BxPC-3 and AsPC-1 were stimulated with EGF, forskolin, or both. Forskolin is a compound that increases cyclic adenosine monophosphate levels. Assays of cell lines were then obtained for cellular growth (MTT assay), anchorage-independent growth (soft agar), and EGF-induced mitogen-activated protein kinase activation as measured by an in-gel kinase assay. RESULTS: Treatment with forskolin resulted in inhibition of EGF-induced activation of mitogen-activated protein kinase activity (BxPC-3 78% inhibition and AsPC-1 70% inhibition, p < 0.005), diminished cellular proliferation (BxPC-3 92% inhibition and AsPC-1 86% inhibition, p < 0.001), and formation of colonies in soft agar (BxPC-3 98% inhibition and AsPC-1 76% inhibition, p < 0.001). Forskolin did not inhibit EGF receptor autophosphorylation or tyrosine kinase signaling in response to EGF. CONCLUSIONS: Forskolin-induced inhibition of mitogen-activated protein kinase is associated with diminished pancreatic cancer cell proliferation in vitro. Use of strategies to increase cyclic adenosine monophosphate levels may have therapeutic application in pancreatic cancer.


Subject(s)
Adenocarcinoma , Cyclic AMP/metabolism , Epidermal Growth Factor/physiology , Pancreatic Neoplasms , Signal Transduction/physiology , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cell Culture Techniques , Cell Division/physiology , ErbB Receptors/metabolism , Humans , Phosphorylation , Phosphotyrosine/metabolism , Tumor Cells, Cultured/chemistry , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/metabolism
13.
Ann Surg ; 222(5): 638-45, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7487211

ABSTRACT

OBJECTIVE: The authors examined the effect of hospital and surgeon volume on perioperative mortality rates after pancreatic resection for the treatment of pancreatic cancer. METHODS: Discharge abstracts from 1972 patients who had undergone pancreaticoduodenectomy or total pancreatectomy for malignancy in New York State between 1984 and 1991 were obtained from the Statewide Planning and Research Cooperative System. Logistic regression analysis was used to determine the relationship between hospital and surgeon experience to perioperative outcome. RESULTS: More than 75% of patients underwent resection at minimal-volume (fewer than 10 cases) or low-volume (10-50 cases) centers (defined as hospitals in which a minimal number of resections were performed in a given year), and these hospitals represented 98% of the institutions treating peripancreatic cancer. The two high-volume hospitals (more than 81 cases) demonstrated a significantly lower perioperative mortality rate (4.0%) compared with the minimal- (21.8%) and low-volume (12.3%) hospitals (p < 0.001). The perioperative mortality rate was 15.5% for low-volume (fewer than 9 cases) surgeons (defined as surgeons who had performed a minimal number of resections in any hospital in a given year) (n = 687) compared with 4.7% for high-volume (more than 41 cases) pancreatic surgeons (n = 4) (p < 0.001). Logistic regression analysis demonstrated that perioperative death is significantly (p < 0.05) related to hospital volume, but the surgeon's experience is not significantly related to perioperative deaths when hospital volume is controlled. CONCLUSIONS: These data support a defined minimum hospital experience for elective pancreatectomy for malignancy to minimize perioperative deaths.


Subject(s)
General Surgery , Health Facility Size/statistics & numerical data , Pancreatectomy/mortality , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/surgery , Pancreaticoduodenectomy/mortality , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Infant , Logistic Models , Male , Middle Aged
14.
J Thorac Cardiovasc Surg ; 109(1): 130-8; discussion 139, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7815789

ABSTRACT

Previous investigators have reported that in patients with esophageal carcinoma tumor cell type affects prognosis. A retrospective analysis of 258 patients, from 1985 to 1991, undergoing curative esophagogastrectomy for adenocarcinoma (n = 134) or squamous cell carcinoma (n = 124) was performed to test the hypothesis that histologic cell type is an independent prognostic factor and to identify other predictors of survival after resection. The actuarial overall survival (p = 0.16) and disease-specific survival (p = 0.68) were similar for adenocarcinoma (median overall survival = 27 months) and squamous cell carcinoma (median overall survival = 22 months). Univariate analysis identified T stage, N stage, number of diseased nodes, tumor differentiation, tumor site, and blood transfusions as significant (p < 0.05) variables in predicting overall survival. The presence of Barrett's esophagus was not predictive of survival. Multivariate analysis demonstrated that T stage (p = 0.006), N stage (p = 0.01), and number of diseased lymph nodes (p = 0.03) were independent predictors of overall survival. This analysis demonstrated that histologic type is not an independent variable for overall survival in patients undergoing curative esophagogastrectomy for carcinoma of the esophagus and gastroesophageal junction. Outcome is most strongly influenced by extent of disease defined by T and N stage.


Subject(s)
Adenocarcinoma/pathology , Carcinoma, Squamous Cell/pathology , Esophageal Neoplasms/pathology , Actuarial Analysis , Adenocarcinoma/mortality , Aged , Carcinoma, Squamous Cell/mortality , Esophageal Neoplasms/mortality , Esophagectomy , Esophagogastric Junction/surgery , Female , Gastrectomy , Humans , Male , Middle Aged , Prognosis , Retrospective Studies
15.
J Thorac Cardiovasc Surg ; 108(6): 1138-46, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7983884

ABSTRACT

The clinical behavior and response to therapy of rare histologic variants of esophageal carcinoma are unclear. To evaluate the results of therapy in this group the records of 29 patients treated between 1949 and 1991 with primary rare histologic variants of esophageal carcinoma were retrospectively reviewed. This group represented 1.2% of 2454 cases of esophageal carcinoma treated between 1949 and 1991 and included mucoepidermoid (n = 14), small-cell (n = 12), adenoid cystic (n = 2), and carcinosarcoma (n = 1) carcinomas. Treatment for localized disease consisted of esophagectomy in five of seven patients with mucoepidermoid carcinoma, two of six patients with small-cell carcinoma, two of two patients with adenoid cystic carcinoma, and one of one patient with carcinosarcoma. Patients with stage IV mucoepidermoid carcinoma were treated predominately with radiation therapy (5/7). The majority of small cell carcinomas were treated with multiagent chemotherapy (10/12). The 1- and 3-year disease-specific survivals were 54% and 9% for mucoepidermoid carcinoma (median survival, 5 months) and 16% and 0% for small-cell carcinoma (median survival, 7 months), respectively. Patients with stage III mucoepidermoid carcinoma (median survival, 20.5 months) compared with those with stage III small-cell carcinoma (median survival, 6.2 months) had a significantly longer duration of survival (p < 0.05). Distant disease was present in 86% of patients in whom recurrence developed after esophagectomy Esophagectomy is standard therapy for localized carcinomas of the esophagus. Small-cell carcinoma appears to be a more aggressive variant of carcinoma and is most commonly treated with chemotherapy.


Subject(s)
Carcinoma/diagnosis , Esophageal Neoplasms/diagnosis , Adult , Aged , Carcinoma/mortality , Carcinoma/pathology , Carcinoma/therapy , Combined Modality Therapy , Esophageal Neoplasms/mortality , Esophageal Neoplasms/pathology , Esophageal Neoplasms/therapy , Female , Humans , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Prevalence , Retrospective Studies , Survival Analysis , Time Factors
16.
J Vasc Surg ; 18(1): 81-9, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8326663

ABSTRACT

When failure of vein grafts is due to technical error it is usually observed in the early postoperative period. In this review we describe late failure of five bypass grafts as a result of entrapment of the vein graft caused by an improperly placed tunnel from the femoral to the popliteal artery. Vein graft entrapment may either produce no symptoms or eventually lead to limb ischemia. Pulses and pressures that vary with flexion and extension maneuvers should alert the clinician to the possibility of an entrapment syndrome. The characteristic arteriographic findings observed in these patients include an aberrant course of the vein graft outside the anatomic course of the popliteal artery and position-dependent compression of the graft. The ability of magnetic resonance angiography to demonstrate the arteriographic appearance of the graft as well as the precise location of the compression and to identify structures involved in the entrapment, make it a valuable noninvasive tool in the preoperative assessment of these patients. Treatment options include division of the gastrocnemius muscle, division of the vein graft, or replacement of the vein graft. Familiarity with vein graft entrapment should facilitate its recognition. Careful placement of bypass grafts along the anatomic course of the popliteal artery within the popliteal space will prevent this complication.


Subject(s)
Graft Occlusion, Vascular/etiology , Iatrogenic Disease , Saphenous Vein/transplantation , Aged , Angiography , Femoral Artery/surgery , Graft Occlusion, Vascular/diagnostic imaging , Graft Occlusion, Vascular/pathology , Humans , Ischemia/etiology , Leg/blood supply , Male , Middle Aged , Popliteal Artery/surgery , Postoperative Complications , Saphenous Vein/diagnostic imaging , Saphenous Vein/pathology
17.
Surgery ; 112(1): 56-67, 1992 Jul.
Article in English | MEDLINE | ID: mdl-1377838

ABSTRACT

The individual nutrients arginine, RNA, and omega-3 fatty acids improve immune function, but prospective trials have not demonstrated their effects on clinical outcome. Patients (n = 85) who underwent operation for upper gastrointestinal malignancies were randomized to receive the supplemental diet or a standard enteral diet after surgery. Clinical patient characteristics were similar between the two groups. Mean caloric intakes (1421 vs 1285 kcal/day) were similar between groups. Mean nitrogen intakes (15.6 vs 9.0 gm/day) and nitrogen balances (-2.2 vs -6.6 gm/day) measured in the first 20 patients were significantly greater in the supplemented group than in the standard group (p = 0.05). In vitro lymphocyte mitogenesis was measured in the first 31 patients and was decreased on postoperative day 1 in both groups, but normal levels were regained only in the supplemented group. In the cohort of 77 eligible patients, infectious and wound complications occurred significantly less often (11% vs 37%) in the supplemented group than in the standard group (p = 0.02). Linear logistic models for infectious/wound complications with control for the amount of nitrogen suggested (p = 0.10) dietary treatment as the major factor. Mean length of stay in the hospital was significantly shorter (p = 0.01) for the supplemented group (15.8 +/- 5.1 days) than for the standard group (20.2 +/- 9.4 days). These results suggest that postoperative enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids instead of a standard enteral diet significantly improved immunologic, metabolic, and clinical outcomes in patients with upper gastrointestinal malignancies who were undergoing major elective surgery.


Subject(s)
Amino Acids/blood , Arginine/administration & dosage , Enteral Nutrition , Fatty Acids, Omega-3/administration & dosage , Gastrointestinal Neoplasms/surgery , Lymphocytes/immunology , Nitrogen/metabolism , Nutritional Status , RNA/administration & dosage , Aged , Cohort Studies , Energy Intake , Female , Humans , Life Tables , Lymphocyte Activation , Male , Middle Aged , Regression Analysis , Treatment Outcome , Wound Healing
18.
Ann Surg ; 215(2): 157-65, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1546902

ABSTRACT

Nutrient substrates have been shown to enhance cell-mediated immunity, but their role as adjuvants to immunotherapy has not been previously determined. This study evaluated L-arginine as an essential substrate for optimal generation of lymphokine-activated killer (LAK) cells. This experiment also assessed supplemental dietary L-arginine as a means to potentiate the host antitumor response to interleukin-2 (IL-2) in a murine neuroblastoma (NRB) model. A/J mice received 1% arginine or isonitrogenous 1.7% glycine in addition to a regular diet 14 days before subcutaneous inoculation with C1300 NRB cells. Twenty-four hours later, animals received low (1 x 10(6) U/kg three times a day) or high (3 x 10(6) U/kg three times a day) doses of IL-2 or saline intraperitoneally for 4 days. On days 4 and 10 post-C1300 NRB inoculation, mice were killed for assessment of natural killer cell and tumor specific cytotoxicity. Remaining animals were followed for tumor incidence, tumor growth, and duration of host survival. Interleukin-2 therapy in mice receiving dietary arginine compared with those receiving glycine resulted in significantly augmented natural killer cell cytotoxicity (day 4) and generation of specific tumoricidal mechanisms (day 10). The addition of dietary arginine to low-dose IL-2 therapy significantly diminished C1300 NRB engraftment (p less than 0.05) and growth (p less than 0.001) and prolonged the duration of host survival (p less than 0.05) compared with the glycine treatment group. In vitro studies demonstrated that L-arginine is an essential substrate for optimal generation of LAK cells. Thus, supplemental dietary L-arginine enhances lymphocyte cytotoxic mechanisms and potentiates IL-2 immunotherapy.


Subject(s)
Arginine/pharmacology , Interleukin-2/therapeutic use , Neuroblastoma/therapy , Amino Acids/blood , Animals , Chi-Square Distribution , Cytotoxicity, Immunologic/drug effects , Drug Synergism , Killer Cells, Lymphokine-Activated/drug effects , Lymphocyte Activation/drug effects , Male , Mice , Mice, Inbred A , Mice, Inbred BALB C , Neuroblastoma/immunology , Random Allocation , Tumor Cells, Cultured
19.
Surg Clin North Am ; 71(3): 523-36, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1904641

ABSTRACT

Malnutrition is extremely common in patients with malignant disease. Whereas the causes are multifactorial, the predominant factor is the imbalance between nutrient intake and host nutrient requirements. Furthermore, the evidence suggests that cachexia is related to abnormal changes in host intermediary metabolism induced by host-tumor interactions, and endogenous peptides such as TNF may be important mediators. The role of nutritional therapy in cancer patients remains to be defined. Clearly, patients with severe malnutrition benefit from nutritional intervention. However, the benefit of nutritional therapy in less severe cases of malnutrition as an adjuvant to oncologic therapy has yet to be established.


Subject(s)
Enteral Nutrition , Gastrointestinal Neoplasms/therapy , Nutrition Disorders/therapy , Parenteral Nutrition , Cachexia/etiology , Gastrointestinal Neoplasms/complications , Humans , Nutrition Disorders/etiology , Nutritional Status
20.
JPEN J Parenter Enteral Nutr ; 15(3): 307-12, 1991.
Article in English | MEDLINE | ID: mdl-1865552

ABSTRACT

Administration of chemotherapy is limited by host toxicity, which is often manifested by severe enterocolitis. This study evaluated the effects of a liquid, elemental, chemically defined diet (ED) supplemented with 2% glutamine (Glu-ED) compared with a polypeptide diet (PPD) on the morbidity and mortality after methotrexate (MTX) administration. Fischer 344 rats (n = 80) were fed either a regular rat chow diet (RD), a 2% glycine supplemented elemental diet (Gly-ED), a 2% glutamine-supplemented elemental diet (GLU-ED), and a glycine-supplemented polypeptide diet(Gly-PPD) for 7 days prior to administration of MTX (20 mg/kg, ip). After 72 hours, eight rats per group were killed; portal vein and vena cava blood, mesenteric lymph nodes (MLN), liver, small intestine, and cecum were sampled for bacterial culture. Remaining animals were followed to calculate survival. One hundred percent of the Gly-PPD and 25% of the Glu-ED animals survived compared with 0% of the Gly-ED animals. Our data showed that ED resulted in an increased quantity of intestinal Gram-negative bacteria and diminished intestinal mucosal height and mucosal DNA/protein content. The polypeptide diet prevented intestinal mucosal atrophy, avoided MTX-induced enterocolitis and significantly improved animal survival compared with an elemental diet with or without glutamine supplementation.


Subject(s)
Enterocolitis/diet therapy , Methotrexate/toxicity , Animals , Bacteria, Aerobic/isolation & purification , Bacteria, Anaerobic/isolation & purification , Cecum/microbiology , Energy Intake , Enterocolitis/chemically induced , Enterocolitis/pathology , Glutamine/administration & dosage , Glutamine/therapeutic use , Glycine/administration & dosage , Glycine/therapeutic use , Intestinal Mucosa/pathology , Liver/microbiology , Lymph Nodes/microbiology , Male , Peptides/administration & dosage , Peptides/therapeutic use , Rats , Rats, Inbred F344
SELECTION OF CITATIONS
SEARCH DETAIL
...